reports
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc 08-Apr-2025 / 14:46 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(...
Puretech Health: 3 directors
Three Directors at Puretech Health sold 767,533 shares at 250p. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
- Edward Thomason
- Seb Jantet
LIBERUM: PureTech Health* - Prelims set scene for future catalysts
2022 was an eventful year for PureTech and its affiliates, and the company had success in creating and returning value to shareholders. Today’s prelims are positive, with cash slightly better than anticipated although there is no material new news released. Instead, the scene is set for an important 12-18 months with three important data readouts this year for the internal pipeline. The most pertinent is the pivotal trial data for LYT-100. We remain buyers ahead of these catalysts with a refresh...
- Liberum Research Team
- Liberum Research Team
- Edward Thomason
- Seb Jantet
LIBERUM: PureTech Health - Royalty deal offers upside
The KarXT royalty deal announced today with Royalty Pharma is attractively priced and, at a material premium to our previous fair value estimate. Our analysis indicates that today’s deal adds 62p to PureTech’s valuation. This gain is partially offset by updating the pricing of PureTech’s listed entities, so the net result is that our target price has increased by 50p to 470p. Even after today’s increase, the shares continue to look very undervalued and we reiterate our Buy recommendation.
- Liberum Research Team
APH ALLIANCE PHARMA PLC
RYA RYANAIR
SFE SAFESTYLE UK
PRTC PURETECH HEALTH
LMP LONDONMETRIC PROPERTY PLC
FEVR FEVERTREE DRINKS PLC
XPS XPS PENSIONS GROUP
HONY HONEYCOMB INVESTMENT TRUST
WIX WICKES GROUP PLC
BYIT BYTES TECHNOLOGY GROUP PLC
A11 ATLANTIC LITHIUM LIMITED
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
- Liberum Research Team
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc 10-Oct-2022 / 14:18 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests an...
Sonde Health Appoints Thai Lee to Board of Directors
BOSTON--(BUSINESS WIRE)-- Sonde Health Inc., an affiliate of PureTech Health (PureTech Health plc, PRTC.L) developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced that Thai Lee, President and Chief Executive Officer of SHI International Corporation, has joined Sonde’s Board of Directors. Ms. Lee brings a wealth of experience in building and scaling-up one of the largest information technology solutions companies in the world, with $10 billion of annual s...
PureTech Health Appoints Joep Muijrers as Chief Financial Officer
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) (“PureTech Health” or the “Company”), an advanced, clinical-stage biopharmaceutical company, is pleased to announce today the appointment of Joep Muijrers, as the Company’s Chief Financial Officer after 11 successful years as a Partner and Portfolio Manager at LSP (Life Sciences Partners), a trans-Atlantic investor group with exclusive focus on life sciences, where he helped several companies become leaders in the biopharma industry and generated tremendous value for his firm’s...
Sonde Health Announces U.S. and Australian Patent Issuances Broadly Co...
BOSTON--(BUSINESS WIRE)-- Sonde Health Inc., an affiliate of PureTech Health (PureTech Health plc, PRTC.L) developing a voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, today announced that the United States Patent and Trademark Office (USPTO) and Intellectual Property Australia (IP Australia) have issued U.S. Patent No. 9,936,914 and Australian Patent No. 2014374349. The U.S. patent, which provides coverage until 2032, is focused on extracting proprietary acoustic features f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.